The screening for HCC in chronic liver disease is:
**Core Concept**
The screening for hepatocellular carcinoma (HCC) in chronic liver disease is crucial due to the high risk of developing this malignancy. **Alpha-fetoprotein (AFP)** levels are often elevated in HCC, making it a potential tumor marker. However, AFP levels can also be elevated in other conditions, limiting its specificity.
**Why the Correct Answer is Right**
The correct answer is **A.**. This is because **serum AFP levels** are commonly used as a screening tool for HCC in patients with chronic liver disease. Elevated AFP levels can indicate the presence of HCC, although a normal level does not rule out the disease. The American Association for the Study of Liver Diseases (AASLD) recommends screening for HCC in patients with chronic liver disease using a combination of imaging studies and AFP levels.
**Why Each Wrong Option is Incorrect**
**Option B:** This option is incorrect because **Liver function tests (LFTs)** are not specific for HCC and can be abnormal in various liver conditions. While LFTs can indicate liver damage, they do not directly screen for HCC.
**Option C:** This option is incorrect because **CT or MRI scans** are imaging modalities used to diagnose HCC, but they are not a primary screening tool. These tests are typically used when AFP levels are elevated or when there is a high suspicion of HCC.
**Option D:** This option is incorrect because **Ultrasound** is a useful imaging modality, but it is not the primary screening tool for HCC. Ultrasound can detect liver lesions, but it may not be as sensitive as other imaging modalities in detecting HCC.
**Clinical Pearl / High-Yield Fact**
The **Glasgow-ALBI score** is a useful tool for predicting the risk of HCC in patients with chronic liver disease. This score combines AFP levels with liver function tests to estimate the risk of HCC.
**Correct Answer: A. Serum AFP levels.**